Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2020

View Archived Issues

Microbiome metabolites as immunotherapy adjuvants

Oxygen therapy harms lungs via lung, gut microbiome

Positive preclinical data presented for multi-target COVID-19 vaccine

T-2143, a novel HSP90-PI3K drug conjugate with promising activity in cancer models

Discovery of a novel FASN inhibitor with promising activity in model of AD

BrightGene Bio-Medical Technology identifies Gly12Cys mutant GTPase KRAS inhibitors

New PD-1/PD-L1 and/or PD-L1/CD80 interaction inhibitors patented by Betta Pharmaceuticals

Jiangsu Vcare Pharmatech discovers JAK inhibitors

Zhejiang Hisun Pharmaceutical presents new RET inhibitors

University of Queensland, Preveceutical Medical patent delta- and kappa-opioid receptor antagonists

Update on development of PGX-YBG inhalable therapeutic for COVID-19

First patient dosed in phase Ib study of ARO-HIF2 in clear cell renal cell carcinoma

Topline data presented from phase II study of elobixibat in NAFLD and NASH

FDA issues complete response letter for filgotinib for the treatment of RA

Promising interim data presented from phase II study of ERC-1671 in recurrent GBM

Phase II study of QBECO SSI in colorectal cancer approved in Israel

Evotec and Novo Nordisk collaborate to develop novel therapies for CKD

Targeting the adenosine A2A receptor may prevent osteoarthritis progression

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...